Full-Time

Regional Account Director

Confirmed live in the last 24 hours

Deadline 9/5/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Compensation Overview

$157.5k - $227.5k/yr

Senior, Expert

Cambridge, MA, USA + 4 more

More locations: Boston, MA, USA | Manchester, NH, USA | Montpelier, VT, USA | Portland, ME, USA

Hybrid

Field-based role requiring greater than 50% travel to the listed locations.

Category
Strategic Account Management
Sales & Account Management
Requirements
  • Bachelor's degree required; Master’s/advanced degree preferred
  • 2+ years of direct managed care experience
Responsibilities
  • Implements strategies and tactics to support appropriate formulary placement and reimbursement (coverage, coding, payment, and patient access) across assigned customers
  • Negotiates cost effective contracts that allow access to our products by providers and their patients
  • Responsible for positive business outcomes within assigned accounts
  • Creates clear messages for dissemination to sales on important payer trends, reimbursement changes, and billing requirements that will positively impact product utilization
  • Represents the Market Access organization, with professionalism and integrity, at national payer organizations and SPP meetings and internally with various departmental and leadership teams
  • Maintains accurate account information within customer databases
  • Partner with the various product PSS and case managers to assure accurate coverage determinations and resolve customer issues.
Desired Qualifications
  • 5+ years field-based pharmaceutical/biotech Sales and/or Marketing experience preferred
  • Established positive relationships with Pharmacy Directors and Medical Directors within key assigned accounts
  • Demonstrated knowledge of payer decision-making for formulary processes, coverage, coding and patient access to drugs, biologicals, medical devices
  • Experience in Specialty Pharmacy and patient support services
  • Experience with medical benefit products
  • Therapeutic experience in Immunology, Diabetes, Neurology, Oncology, Rare Diseases and/or Rare Blood Disorders
  • Experience negotiating contracts and agreements
  • Exceptional communication skills that include verbal, written and presentation abilities
  • Demonstrated problem-solving capabilities
  • Outstanding consultative and networking capabilities
  • Excellent project management skills, with the ability to handle multiple tasks at one time
  • Ability to skillfully negotiate in tough situations with both internal and external groups.
  • Understanding of organizational behavior, culture and be able to flourish in a complex and rapidly evolving workplace.
  • Skilled to successfully lead account teams through collaboration with other members within and across sales, marketing, reimbursement, and other business groups to improve overall effectiveness.

Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new therapies for conditions like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and a diverse product pipeline, supported by strategic partnerships. The company's goal is to enhance health outcomes and improve the quality of life for people globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Blueprint Medicines expands its portfolio in rare immunological diseases.
  • The approval of Dupixent for chronic spontaneous urticaria opens new market opportunities.
  • Sanofi's investment in Adagene supports innovative cancer treatment development.

What critics are saying

  • Large-scale acquisitions may strain Sanofi's financial stability if returns are insufficient.
  • Regulatory challenges could delay the market entry of new treatments like tolebrutinib.
  • Dependence on strategic partnerships may pose risks if collaborations don't meet expectations.

What makes Sanofi unique

  • Sanofi's extensive R&D efforts focus on unmet medical needs in immunology and oncology.
  • The company leverages strategic partnerships to enhance its product pipeline and market reach.
  • Sanofi's global presence allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Investors Hangout
Jul 1st, 2025
Adagene Secures $25M Investment from Sanofi

Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...